AYTU BioPharma, Inc. (AYTU), formerly Aytu BioScience, Inc., is a specialty pharmaceutical company operating from Englewood, Colorado, USA. It primarily focuses on the commercialization of novel products in the therapeutics market. The organization is committed to introducing innovative therapeutic options to improve the health and well-being of patients worldwide. The company plays a substantial role in filling significant treatment gaps in patient care, using its extensive and unique pharmaceutical knowledge and expertise.
Established in 2015, AYTU BioPharma has targeted a diverse range of medical areas such as pediatrics, urology, and respiratory diseases. It has developed and commercialized several innovative products, mainly consisting of diagnostics and therapeutics. AYTU's prominent offerings include the Natesto nasal gel, intended for testosterone replacement therapy; ZolpiMist, an oral spray for insomnia; and Tuzistra XR for cough and respiratory ailments.
Additionally, AYTU BioPharma utilizes its distribution platform to commercialize a broad range of novel diagnostic tests. It entered the spotlight with its quick distribution of COVID-19 IgG/IgM rapid tests amid the global pandemic which reinforced its commitment to public health needs.
AYTU BioPharma's growth strategy is underpinned by a focus on novel product acquisitions, internal product development, and robust market launches. They are constantly exploring opportunities to expand their portfolio by seeking products and technologies that address significant patient needs in large and growing markets.
More recently, the company has made its foray into the rapidly evolving field of psychedelic medicine by acquiring the rights to the novel drug candidate NLS-1, a formulation of the psychedelic compound DMT.
AYTU BioPharma, Inc is publicly traded on NASDAQ under its ticker symbol 'AYTU'. It operates as a relatively small player in the vast pharmaceutical industry but continues to show its value by developing and bringing to market a range of innovative healthcare solutions. With a bustling pipeline and a proactive approach to addressing unmet medical needs, AYTU BioPharma is well geared to establish its presence and make significant strides in the global pharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aytu BioPharma Inc. reported its Q4 FY2026 earnings, highlighting significant acceleration in EXXUA net revenue and prescriptions, alongside improved commercial productivity. The company achieved positive adjusted EBITDA in Q4 and expects continued profitability into the second half of fiscal 2027, despite some sales force adjustments and a net loss for the full fiscal year. Growth in the ADHD portfolio and stable cash reserves further underpin its financial position.
Aytu BioPharma, Inc. (AYTU) reported a Q4 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.22 loss, and beating revenue estimates with $16.11 million. Despite beating expectations, the company's shares have lost 18.3% year-to-date. The stock currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Aytu BioPharma reported fiscal Q4 2026 revenue of $16.1 million, a 6.4% increase year-over-year, driven partly by EXXUA which generated $3.9 million in the quarter. Despite an annual revenue decline for fiscal 2026, the company saw significant growth in EXXUA prescriptions, and its adjusted EBITDA turned positive for the fourth quarter. Institutional investors showed mixed activity in AYTU stock during Q1 and Q2 2026.
Aytu BioPharma, Inc. announced that it will report its fiscal 2026 full-year and fourth-quarter operational and financial results after market close on Tuesday, September 22, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results. Aytu BioPharma focuses on developing innovative medicines for complex central nervous system diseases, including treatments for major depressive disorder (MDD) and ADHD.